Short at­tack­er Sahm Ad­ran­gi draws crosshairs over a fa­vorite of Sanofi’s new CEO — with PhII da­ta loom­ing

Sahm Ad­rang Ker­ris­dale

Ker­ris­dale chief Sahm Ad­ran­gi took a lengthy break from his se­ries of biotech short at­tacks af­ter his chief an­a­lyst in the field pulled up stakes and went so­lo. But he’s mak­ing a re­turn to drug de­vel­op­ment this morn­ing, draw­ing crosshairs over a com­pa­ny that’s one of new Sanofi CEO Paul Hud­son’s fa­vorite col­lab­o­ra­tors.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER